-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
ImmunoGen (NASDAQ:IMGN) Earns Overweight Rating From Analysts at Barclays
ImmunoGen (NASDAQ:IMGN) Earns Overweight Rating From Analysts at Barclays
Barclays began coverage on shares of ImmunoGen (NASDAQ:IMGN – Get Rating) in a research note issued to investors on Friday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $8.00 price target on the biotechnology company's stock.
Separately, StockNews.com downgraded shares of ImmunoGen from a hold rating to a sell rating in a research note on Monday, August 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and an average price target of $9.80.
Get ImmunoGen alerts:ImmunoGen Stock Down 0.4 %
NASDAQ:IMGN opened at $5.44 on Friday. The company has a fifty day simple moving average of $5.40 and a two-hundred day simple moving average of $4.84. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -7.88 and a beta of 0.90. ImmunoGen has a 52 week low of $3.10 and a 52 week high of $7.77.
ImmunoGen (NASDAQ:IMGN – Get Rating) last posted its quarterly earnings results on Friday, July 29th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.03). The business had revenue of $14.20 million during the quarter, compared to analyst estimates of $16.18 million. ImmunoGen had a negative return on equity of 67.02% and a negative net margin of 179.64%. The business's revenue was down 16.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.15) EPS. On average, analysts expect that ImmunoGen will post -0.89 EPS for the current year.Hedge Funds Weigh In On ImmunoGen
A number of institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Arbitrage SA grew its stake in shares of ImmunoGen by 4.1% during the fourth quarter. BNP Paribas Arbitrage SA now owns 61,561 shares of the biotechnology company's stock worth $457,000 after purchasing an additional 2,406 shares in the last quarter. TFC Financial Management grew its stake in shares of ImmunoGen by 18.1% during the first quarter. TFC Financial Management now owns 17,950 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 2,750 shares in the last quarter. Blair William & Co. IL grew its stake in shares of ImmunoGen by 0.5% during the first quarter. Blair William & Co. IL now owns 538,410 shares of the biotechnology company's stock worth $2,563,000 after purchasing an additional 2,925 shares in the last quarter. Kestra Advisory Services LLC grew its stake in shares of ImmunoGen by 14.6% during the first quarter. Kestra Advisory Services LLC now owns 23,468 shares of the biotechnology company's stock worth $112,000 after purchasing an additional 2,985 shares in the last quarter. Finally, Mackenzie Financial Corp grew its stake in shares of ImmunoGen by 4.4% during the first quarter. Mackenzie Financial Corp now owns 80,816 shares of the biotechnology company's stock worth $385,000 after purchasing an additional 3,370 shares in the last quarter. Institutional investors and hedge funds own 95.58% of the company's stock.
About ImmunoGen
(Get Rating)
ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
Featured Articles
- Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.
Barclays began coverage on shares of ImmunoGen (NASDAQ:IMGN – Get Rating) in a research note issued to investors on Friday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $8.00 price target on the biotechnology company's stock.
據MarketBeat Ratings報道，巴克萊在週五向投資者發佈的一份研究報告中開始對免疫系統(納斯達克代碼：IMGN-GET Rating)的股票進行報道。該經紀公司對這家生物技術公司的股票發佈了增持評級和8.00美元的目標價。
Separately, StockNews.com downgraded shares of ImmunoGen from a hold rating to a sell rating in a research note on Monday, August 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and an average price target of $9.80.
另外，StockNews.com在8月1日星期一的一份研究報告中將ImmunoGen的股票評級從持有評級下調為賣出評級。一名分析師對該股的評級為賣出，兩名分析師發佈了持有評級，三名分析師對該股給予了買入評級。根據MarketBeat.com的數據，該股目前的普遍評級為持有，平均目標價為9.80美元。
ImmunoGen Stock Down 0.4 %
免疫基因公司股價下跌0.4%
NASDAQ:IMGN opened at $5.44 on Friday. The company has a fifty day simple moving average of $5.40 and a two-hundred day simple moving average of $4.84. The company has a market cap of $1.20 billion, a price-to-earnings ratio of -7.88 and a beta of 0.90. ImmunoGen has a 52 week low of $3.10 and a 52 week high of $7.77.
納斯達克：IMGN上週五開盤報5.44美元。該公司的50日簡單移動均線切入位在5.40美元，200日簡單移動均線切入位在4.84美元。該公司市值為12.億美元，市盈率為-7.88倍，貝塔係數為0.90。ImmunoGen的52周低點為3.10美元，52周高位為7.77美元。
Hedge Funds Weigh In On ImmunoGen
對衝基金參與了免疫基因的研究
A number of institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Arbitrage SA grew its stake in shares of ImmunoGen by 4.1% during the fourth quarter. BNP Paribas Arbitrage SA now owns 61,561 shares of the biotechnology company's stock worth $457,000 after purchasing an additional 2,406 shares in the last quarter. TFC Financial Management grew its stake in shares of ImmunoGen by 18.1% during the first quarter. TFC Financial Management now owns 17,950 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 2,750 shares in the last quarter. Blair William & Co. IL grew its stake in shares of ImmunoGen by 0.5% during the first quarter. Blair William & Co. IL now owns 538,410 shares of the biotechnology company's stock worth $2,563,000 after purchasing an additional 2,925 shares in the last quarter. Kestra Advisory Services LLC grew its stake in shares of ImmunoGen by 14.6% during the first quarter. Kestra Advisory Services LLC now owns 23,468 shares of the biotechnology company's stock worth $112,000 after purchasing an additional 2,985 shares in the last quarter. Finally, Mackenzie Financial Corp grew its stake in shares of ImmunoGen by 4.4% during the first quarter. Mackenzie Financial Corp now owns 80,816 shares of the biotechnology company's stock worth $385,000 after purchasing an additional 3,370 shares in the last quarter. Institutional investors and hedge funds own 95.58% of the company's stock.
一些機構投資者和對衝基金最近調整了對該公司的持股。第四季度，法國巴黎銀行套利公司持有的免疫系統股票增加了4.1%。法國巴黎銀行套利公司現在持有這家生物技術公司61,561股股票，價值45.7萬美元，上個季度又購買了2,406股。今年第一季度，TFC金融管理公司持有的免疫系統股票增加了18.1%。TFC金融管理公司現在持有這家生物技術公司17,950股股票，價值85,000美元，上個季度又購買了2,750股。在第一季度，Blair William&Co.IL增持了免疫基因公司的股份0.5%。Blair William&Co.IL現在持有538,410股這家生物技術公司的股票，價值2,563,000美元，上個季度又購買了2,925股。Kestra Consulting Services LLC在第一季度持有的免疫系統股票增加了14.6%。Kestra Consulting Services LLC現在擁有這家生物技術公司23,468股股票，價值11.2萬美元，上個季度又購買了2,985股。最後，麥肯錫金融公司在第一季度增持了免疫基因公司4.4%的股份。麥肯錫金融公司(Mackenzie Financial Corp)目前持有這家生物技術公司80,816股股票，價值385,000美元，此前該公司在上個季度又購買了3,370股。機構投資者和對衝基金持有該公司95.58%的股票。
About ImmunoGen
關於免疫基因
(Get Rating)
(獲取評級)
ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
免疫基因公司是一家臨牀階段的生物技術公司，開發抗體-藥物結合(ADC)療法來治療癌症。該公司的候選產品包括針對葉酸受體α(FRA)的ADC Mirvetuximab soravtansine，它正處於治療對鉑耐藥的卵巢癌的第三階段臨牀試驗；以及Pivekimab Sunirine，一種針對CD123的ADC，正處於治療急性髓系白血病和原始漿細胞樣樹突狀細胞腫瘤的第二階段臨牀試驗。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
- Darden Restaurants Takes the Low Road Against Inflation
- Why These 3 Stocks Are Off to Hot September Starts
- Inflation Doesn't Differentiate, But it's Impact Does
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 免費獲取StockNews.com關於免疫基因的研究報告(IMGN)
- 達頓餐廳走低通脹之路
- 這3只股票為何在9月火爆開盤
- 通貨膨脹沒有差別，但它的影響有差別
- 3只被降級的必備股票放在你的觀察名單上
- 這是對第三季度收益報告季節的預期
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.
接受《免疫基因日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收最新新聞和分析師對免疫系統及相關公司評級的每日簡明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧